enGene Holdings Inc. Stock Price, News & Analysis

enGene Holdings (Nasdaq: ENGN) has announced the granting of inducement equity awards to seven newly-hired employees effective April 2, 2025. The awards comprise non-qualified stock options to purchase a total of 144,650 common shares at an exercise price of $4.44 per share, matching the closing price on the grant date.

The stock options feature a 10-year term with a four-year vesting schedule: 25% vesting after one year of employment, followed by monthly vesting over three years. These grants, approved by the Company's independent Compensation Committee, serve as employment inducements under NASDAQ Rule 5635(c)(4).

enGene Holdings (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, has announced its participation in the upcoming Stifel 2025 Virtual Targeted Oncology Forum. Ron Cooper, Chief Executive Officer, will deliver a presentation on Tuesday, April 8, 2025, at 4:00 p.m. ET.

The presentation will be accessible through a live webcast under the 'Investors' section of enGene's website at www.engene.com. The recording will remain available on the website for 90 days following the event.

enGene Holdings (Nasdaq: ENGN) reported Q1 2025 financial results and provided updates on its LEGEND study of detalimogene in BCG-unresponsive NMIBC. The company expanded trial sites into Europe and Asia, with all four LEGEND cohorts now open for enrollment. The study includes a new maintenance dosing protocol allowing complete responders to continue treatment for up to three years.

Financial highlights:

• Cash position: $272.8 million, providing runway into 2027
• Q1 2025 operating expenses: $26.6 million (vs $10.8 million in Q1 2024)
• Net loss: $24.6 million ($0.48 per share)
• R&D expenses increased by $14.3 million due to LEGEND study costs

The company remains on track for its planned Biologics License Application (BLA) filing in mid-2026, with additional preliminary data from the LEGEND study expected in H2 2025.

enGene Holdings (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. Ron Cooper, Chief Executive Officer, will engage in a fireside chat at the conference, which is scheduled for Tuesday, March 11, 2025, at 1:00 p.m. ET in Miami, FL.

Interested parties can access a live webcast of the presentation through the 'Investors' section of enGene's website at www.engene.com. The webcast recording will remain available on the website for 90 days following the event.

enGene Holdings (Nasdaq: ENGN) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's Chief Strategy and Operations Officer, Dr. Alex Nichols, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 8:40 a.m. ET.

enGene is currently conducting a pivotal study of its non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, previously EG-70) for patients with high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The presentation will be available via webcast on the company's website under the 'Investors' section and will remain accessible for 90 days.

enGene Holdings (Nasdaq: ENGN) has granted inducement equity awards to seven newly-hired employees effective January 29, 2025. The awards consist of non-qualified stock options to purchase a total of 262,900 common shares at an exercise price of $7.39 per share, matching the closing price on the grant date.

The stock options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining vesting monthly over three years, contingent on continued employment. These grants were approved by the Company's independent Compensation Committee as employment inducements under NASDAQ Rule 5635(c)(4).

enGene is currently conducting a pivotal study of its non-viral lead investigational product detalimogene voraplasmid for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.

enGene Holdings (Nasdaq: ENGN) announced three poster presentations at the 2025 ASCO Genitourinary Cancers Symposium, showcasing their lead investigational product detalimogene voraplasmid. The treatment targets high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).

The company's pivotal LEGEND study is actively enrolling patients across the USA, Canada, Europe, and Asia-Pacific. The treatment utilizes enGene's Dually Derivatized Oligochitosan® (DDX) platform, designed to overcome viral gene therapy limitations. There are approximately 730,000 bladder cancer patients in the U.S., with 75-80% being NMIBC cases. Among high-risk NMIBC patients, 50-70% become BCG-unresponsive and experience recurrence or progression.

The presentations will cover preliminary LEGEND study results, mechanism of action details, and a phase 1/2 study of detalimogene voraplasmid intravesical monotherapy.

enGene Holdings (Nasdaq: ENGN) announced inducement equity awards for five new employees, granted on December 27, 2024. The awards include non-qualified stock options to purchase 97,400 common shares at an exercise price of $6.42 per share, matching the closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years. These grants, approved by the Company's independent Compensation Committee, serve as employment inducements under NASDAQ Rule 5635(c)(4).

enGene Holdings (Nasdaq: ENGN) reported its financial results for FY2024 and provided business updates. The company's lead product, detalimogene voraplasmid, showed a 71% complete response rate in preliminary data from the LEGEND study's pivotal cohort for BCG-unresponsive NMIBC patients. The study is now recruiting across all four cohorts with protocol amendments including maintenance dosing.

Financial highlights include $297.9 million in cash and equivalents, providing runway into 2027. Total operating expenses were $62.3 million, up from $26.1 million in 2023. Net loss was $55.1 million ($1.46 per share) compared to $104.7 million ($151.22 per share) in 2023.